Sarah M. Larson

2.8k total citations
74 papers, 749 citations indexed

About

Sarah M. Larson is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Sarah M. Larson has authored 74 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 29 papers in Oncology and 19 papers in Genetics. Recurrent topics in Sarah M. Larson's work include Multiple Myeloma Research and Treatments (23 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Sarah M. Larson is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), CAR-T cell therapy research (21 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Sarah M. Larson collaborates with scholars based in United States, Canada and Spain. Sarah M. Larson's co-authors include John M. Timmerman, James H. Moller, Mark C. Johnson, Wendy Stock, Monica Mead, David D. Hurd, Kathryn Trinkaus, Kristie A. Blum, Marilyn J. Siegel and Nancy L. Bartlett and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarah M. Larson

64 papers receiving 738 citations

Peers

Countries citing papers authored by Sarah M. Larson

Since Specialization

Citations

This map shows the geographic impact of Sarah M. Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah M. Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah M. Larson more than expected).

Fields of papers citing papers by Sarah M. Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah M. Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah M. Larson. The network helps show where Sarah M. Larson may publish in the future.

Co-authorship network of co-authors of Sarah M. Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah M. Larson. A scholar is included among the top collaborators of Sarah M. Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah M. Larson. Sarah M. Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma 2025 ·Immunotherapy ·(unknown), (unknown), Sarah M. Larson	1
2	Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), John M. Timmerman, Patricia A. Young, Herbert Eradat, Sven de Vos, Sarah M. Larson, Monica Mead	0
3	Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups 2024 ·Blood ·(unknown), Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, (unknown), Andrew J. Cowan, (unknown), Sarah M. Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, (unknown), Maria Krevvata, Huiling Pei, Sharmila Patel, (unknown), Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros	1
4	Abstract 4138101: CAR-T-associated Cardiovascular Events are Associated with Increased Resource Utilization 2024 ·Circulation ·Justin Song, Jacqueline Vuong, Monica Mead, Jeffrey Gornbein, Michael B. Rothberg, Chunlian Pan, (unknown), (unknown), Daria Gaut, Herbert Eradat, Gary J. Schiller, S deVos, John M. Timmerman, Ashley Stein-Merlob, Tomas G. Neilan, Sarah M. Larson, (unknown), Syed Mahmood, Eric H. Yang	0
5	Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA 2024 ·Blood ·Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, (unknown), (unknown), (unknown), (unknown), (unknown), Annelore Cortoos, Shuchita Kaila, Shebli Atrash	0
6	P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES 2023 ·HemaSphere ·Salomon Manier, Alexander M. Lesokhin, Mohamad Mohty, Rubén Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah M. Larson, (unknown), Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur Raje, Eric Leip, Sharon T. Sullivan, Mohamed Elmeliegy, Andrea Viqueira, Ajay K. Nooka	3
7	Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results. 2022 ·Journal of Clinical Oncology ·(unknown), (unknown), Lin Liu, Minya Pu, Emily Pittman, Dimitrios Tzachanis, Sarah M. Larson, Nina Shah, Carolyn Mulroney, Edward D. Ball, Aaron S. Rosenberg, Caitlin Costello	2
8	Impact of structured care systems on mortality in intensive care units 2021 ·Intensive Care Medicine ·(unknown), Sarah M. Larson, Erwin Ista, Mathieu van der Jagt, Robert D. Stevens	3
9	Cost-Health Literacy as an Educational Objective in Fellowship Training 2021 ·Journal of Cancer Education ·(unknown), (unknown), Anne Walling, Sarah M. Larson, John A. Glaspy	2
10	Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Gary J. Schiller, Sven de Vos, Herbert Eradat, John M. Timmerman, Sarah M. Larson, Monica Mead	17
11	Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? 2020 ·Bone Marrow Transplantation ·(unknown), John M. Timmerman, Sarah M. Larson, Monica Mead	35
12	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors 2020 ·Cancer Chemotherapy and Pharmacology ·Haeseong Park, (unknown), Nikolaos A. Trikalinos, Sarah M. Larson, Benjamin Tan, Saiama N. Waqar, Rama Suresh, Daniel Morgensztern, Brian A. Van Tine, Ramaswamy Govindan, Jingqin Luo, A. Craig Lockhart, Andrea Wang‐Gillam	11
13	An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma 2019 ·Cancer Research ·Shili Xu, Tianyuan Zhou, (unknown), K. Ryan Trinh, (unknown), Jason T. Lee, Daniel Braas, Nicholas Bayley, Reiko Yamada, (unknown), Joshua Sasine, John M. Timmerman, Sarah M. Larson, Youngsoo Kim, A. Robert MacLeod, Sherie L. Morrison, Harvey R. Herschman	44
14	Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study 2019 ·Leukemia & lymphoma ·Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah M. Larson, Susanne Saußele, Delphine Réa, François‐Xavier Mahon, Moshe Levy, María Teresa Gómez‐Casares, Fabrizio Pane, Franck‐Emmanuel Nicolini, Michael J. Mauro, Oumar Sy, Patricia Martin‐Regueira, Jeffrey H. Lipton	97
15	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study 2015 ·Blood ·Ajai Chari, Saurabh Chhabra, Saad Z. Usmani, Sarah M. Larson, Rubén Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew A. Lunning, Jason Valent, Larry D. Anderson, Chatchada Karanes, Long Kwei, L. Chang, Thorsten Graef, Elizabeth Bilotti, Kevin T. McDonagh	6
16	Gene-modified hematopoietic stem cells for cancer immunotherapy 2014 ·Human Vaccines & Immunotherapeutics ·Sarah M. Larson, Satiro De Oliveira	9
17	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML) 2011 ·Leukemia & lymphoma ·Sarah M. Larson, Nicholas Campbell, Dezheng Huo, Andrew Artz, Yanming Zhang, Devika Gajria, Margaret Green, (unknown), Christopher K. Daugherty, Olatoyosi Odenike, Lucy A. Godley, Elizabeth Hyjek, Sandeep Gurbuxani, Michael J. Thirman, Dorothy A. Sipkins, Koen van Besien, Richard A. Larson, Wendy Stock	21
18	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma 2011 ·Blood ·Todd A. Fehniger, Sarah M. Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, André Goy, Stephanie Schneider, Catherine R. Keppel, Nina D. Wagner‐Johnston, Kenneth R. Carson, Nancy L. Bartlett	136
19	Progress in the treatment of adults with acute lymphoblastic leukemia 2008 ·Current Opinion in Hematology ·Sarah M. Larson, Wendy Stock	26
20	COMPARISON OF THE REGULATION OF CALCITONIN IN SERUM OF OLD AND YOUNG BUFFALO RATS 1980 ·Journal of Endocrinology ·Sherry F. Queener, Norman H. Bell, Sarah M. Larson, (unknown), Eduardo Slatopolsky	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact